Free Trial

Relay Therapeutics (RLAY) Competitors

Relay Therapeutics logo
$2.72 -0.27 (-9.03%)
Closing price 04:00 PM Eastern
Extended Trading
$2.76 +0.04 (+1.47%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RLAY vs. ARQT, TARS, HRMY, TVTX, JANX, IRON, AGIO, APGE, MESO, and VERA

Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Mesoblast (MESO), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.

Relay Therapeutics vs.

Arcutis Biotherapeutics (NASDAQ:ARQT) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.

Relay Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Relay Therapeutics' return on equity of -45.75% beat Arcutis Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics-140.97% -119.11% -45.95%
Relay Therapeutics N/A -45.75%-40.75%

Arcutis Biotherapeutics has higher revenue and earnings than Relay Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$196.54M9.50-$262.14M-$1.16-13.56
Relay Therapeutics$10.01M46.08-$341.97M-$2.39-1.14

Arcutis Biotherapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.

Arcutis Biotherapeutics received 6 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 70.45% of users gave Relay Therapeutics an outperform vote while only 66.67% of users gave Arcutis Biotherapeutics an outperform vote.

CompanyUnderperformOutperform
Arcutis BiotherapeuticsOutperform Votes
68
66.67%
Underperform Votes
34
33.33%
Relay TherapeuticsOutperform Votes
62
70.45%
Underperform Votes
26
29.55%

Arcutis Biotherapeutics currently has a consensus target price of $18.80, indicating a potential upside of 19.52%. Relay Therapeutics has a consensus target price of $19.80, indicating a potential upside of 627.94%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Arcutis Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Relay Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 5 mentions for Relay Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.13 beat Relay Therapeutics' score of 0.83 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

97.0% of Relay Therapeutics shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Relay Therapeutics beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks.

Remove Ads
Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLAY vs. The Competition

MetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$461.10M$3.03B$5.63B$7.83B
Dividend YieldN/A1.56%4.57%4.00%
P/E Ratio-1.0428.9323.3318.68
Price / Sales46.08429.70388.4691.04
Price / CashN/A168.6838.1634.64
Price / Book0.463.926.894.23
Net Income-$341.97M-$71.95M$3.20B$247.15M
7 Day Performance-11.11%-5.60%-3.02%-2.17%
1 Month Performance-20.23%-11.96%1.63%-5.68%
1 Year Performance-67.23%-28.47%9.74%-0.67%

Relay Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLAY
Relay Therapeutics
2.4298 of 5 stars
$2.72
-9.0%
$19.80
+627.9%
-63.4%$461.10M$10.01M-1.04330
ARQT
Arcutis Biotherapeutics
2.5337 of 5 stars
$17.29
+1.6%
$18.80
+8.7%
+67.8%$2.05B$196.54M-9.66150Short Interest ↓
Positive News
TARS
Tarsus Pharmaceuticals
2.2392 of 5 stars
$52.36
+4.8%
$63.67
+21.6%
+46.5%$2.01B$182.95M-13.7450Insider Trade
Positive News
HRMY
Harmony Biosciences
4.4516 of 5 stars
$34.24
-2.9%
$53.33
+55.8%
-0.5%$1.96B$714.73M16.23200
TVTX
Travere Therapeutics
2.7735 of 5 stars
$21.29
+3.7%
$30.62
+43.8%
+165.6%$1.89B$233.18M-5.19460News Coverage
Positive News
JANX
Janux Therapeutics
2.6495 of 5 stars
$31.74
+6.0%
$92.44
+191.3%
-21.5%$1.88B$10.59M-27.1330Positive News
IRON
Disc Medicine
2.9556 of 5 stars
$53.70
+2.8%
$93.80
+74.7%
-13.3%$1.86BN/A-13.4930Insider Trade
AGIO
Agios Pharmaceuticals
4.3302 of 5 stars
$32.31
+3.2%
$56.57
+75.1%
+5.9%$1.85B$36.50M2.85390Short Interest ↓
Positive News
APGE
Apogee Therapeutics
2.408 of 5 stars
$40.84
+2.5%
$92.17
+125.7%
-42.4%$1.84BN/A-16.8891Positive News
MESO
Mesoblast
1.8078 of 5 stars
$14.39
+3.2%
$18.00
+25.1%
+281.1%$1.83B$5.67M0.0080Gap Down
VERA
Vera Therapeutics
3.089 of 5 stars
$27.15
+0.3%
$64.67
+138.2%
-39.5%$1.73BN/A-10.4040
Remove Ads

Related Companies and Tools


This page (NASDAQ:RLAY) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners